Rubra Medicaments Stock Price Analysis and Quick Research Report. Is Rubra Medicaments an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Rubra Medicaments stock price today is Rs 13.86. Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Rubra Medicaments . 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Rubra Medicaments has a PE ratio of -39.0642615558061 which is low and comparatively undervalued .

• Share Price: - The current share price of Rubra Medicaments is Rs 13.86. One can use valuation calculators of ticker to know if Rubra Medicaments share price is undervalued or overvalued.

• Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Rubra Medicaments has ROA of 3.8107 % which is a bad sign for future performance. (higher values are always desirable)

• Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Rubra Medicaments has a Current ratio of 2.1426 .

• Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Rubra Medicaments has a ROE of 8.6583 % .(higher is better)

• Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Rubra Medicaments has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

• Sales growth: - Rubra Medicaments has reported revenue growth of -2.5988 % which is poor in relation to its growth and performance. 

• Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Rubra Medicaments for the current financial year is 2.5462831858407 %.

• Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Rubra Medicaments is Rs 0 and the yield is 0 %.

• Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Rubra Medicaments is Rs -0.3548 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Rubra Medicaments in Ticker for free. Also, one can get the intrinsic value of Rubra Medicaments by using Valuation Calculators, which are available with a Finology ONE subscription.